论文部分内容阅读
目的探讨趋化因子受体CXCR4在乳腺癌中的表达及临床意义,为临床治疗乳腺癌寻求新的治疗靶点提供依据。方法采用免疫组化SP染色法检测乳腺癌、乳腺增生组织及乳腺纤维腺瘤中CXCR4表达差异,以及CXCR4在乳腺癌中表达与患者肿瘤分级、淋巴结转移状态、Her2等相互关系。结果CXCR4在乳腺癌组织中高表达,与乳腺增生组织及乳腺纤维腺瘤中表达差异有显著性,而且与患者淋巴结转移状态、Her2、PCNA密切相关。结论CXCR4在乳腺中癌高表达,与患者淋巴结转移状态、Her2、PCNA密切相关,可以作为乳腺癌患者预后的一个指标,为寻找新的乳腺癌治疗靶点提供重要的临床依据。
Objective To investigate the expression and clinical significance of chemokine receptor CXCR4 in breast cancer and provide the basis for clinical treatment of breast cancer. Methods The expression of CXCR4 in breast cancer, hyperplasia of mammary gland and fibroadenoma of breast was detected by immunohistochemical SP staining, and the relationship between the expression of CXCR4 in breast cancer and tumor grade, lymph node metastasis, Her2 and so on. Results The expression of CXCR4 in breast cancer tissues was highly correlated with the expression of CXCR4 in breast hyperplasia and fibroadenoma of breast, which was closely related to the metastasis status of lymph nodes, Her2 and PCNA. Conclusion CXCR4 is highly expressed in breast cancer and closely related to lymph node metastasis, Her2 and PCNA in patients with breast cancer. It may provide an important prognostic indicator for breast cancer and provide an important clinical basis for finding a new therapeutic target for breast cancer.